- Home
- NCSM vs MCRB Comparison
NCSM vs MCRB Comparison
Compare NCSM & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCSM
- MCRB
- Stock Information
- Founded
- NCSM 2006
- MCRB 2010
- Country
- NCSM United States
- MCRB United States
- Employees
- NCSM N/A
- MCRB N/A
- Industry
- NCSM Oilfield Services/Equipment
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- NCSM Energy
- MCRB Health Care
- Exchange
- NCSM Nasdaq
- MCRB Nasdaq
- Market Cap
- NCSM 81.3M
- MCRB 72.0M
- IPO Year
- NCSM 2017
- MCRB 2015
- Fundamental
- Price
- NCSM $28.68
- MCRB $7.01
- Analyst Decision
- NCSM
- MCRB Hold
- Analyst Count
- NCSM 0
- MCRB 5
- Target Price
- NCSM N/A
- MCRB $73.67
- AVG Volume (30 Days)
- NCSM 8.1K
- MCRB 93.5K
- Earning Date
- NCSM 04-30-2025
- MCRB 05-07-2025
- Dividend Yield
- NCSM N/A
- MCRB N/A
- EPS Growth
- NCSM N/A
- MCRB N/A
- EPS
- NCSM 3.27
- MCRB 8.98
- Revenue
- NCSM $168,704,000.00
- MCRB N/A
- Revenue This Year
- NCSM $7.22
- MCRB N/A
- Revenue Next Year
- NCSM $5.43
- MCRB N/A
- P/E Ratio
- NCSM $8.96
- MCRB $0.84
- Revenue Growth
- NCSM 18.16
- MCRB N/A
- 52 Week Low
- NCSM $15.90
- MCRB $6.53
- 52 Week High
- NCSM $38.95
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- NCSM 42.74
- MCRB 39.05
- Support Level
- NCSM $31.12
- MCRB $6.84
- Resistance Level
- NCSM $31.43
- MCRB $7.33
- Average True Range (ATR)
- NCSM 1.28
- MCRB 0.57
- MACD
- NCSM -0.35
- MCRB 0.10
- Stochastic Oscillator
- NCSM 0.00
- MCRB 29.44
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.